Shenzhen News Network, September 11, 2024 (Reporter Cao Yuanfang) On September 10, the "2024 Annual Conference of the Chemistry and Chemical Engineering Professional Committee and the 2024 Annual Conference of the API Professional Committee of the Guangdong Biomedical Innovation Technology Association" was held at the Greater Bay Area International Vaccine Innovation Center in Pingshan Biomedical Industrial Park, Shenzhen. This annual conference is guided by the Science and Technology Innovation Bureau of Pingshan District, Shenzhen City, and jointly organized by the Pingshan Biomedical Research Institute of Southern University of Science and Technology, Shenzhen Huaxian Pharmaceutical Technology Co., Ltd. and the Chemistry and Chemical Engineering Professional Committee. It is jointly organized by the Guangdong Biomedical Innovation Technology Association, the Shenzhen Life Science and Biotechnology Association, Guangdong Raffles Pharmaceutical Technology Co., LTD., the Shenzhen Pingshan District Small Molecule New Drug Innovation Association, and the Greater Bay Area International Vaccine Innovation Center.

Liu Weidong, the chairperson of the Science and Technology Association of the Science and Technology Innovation Bureau of Pingshan District, Shenzhen City, Zhang Xumu, a foreign academician of the Russian Academy of Engineering and the director of the Pingshan Biomedical Research Institute of Southern University of Science and Technology, He Zhendan, a foreign academician of the Russian Academy of Engineering and the dean of the School of Pharmacy of Shenzhen University of Technology, Li Wenbao, a professor at the School of Life Sciences of the University of Chinese Academy of Sciences, and Wang Peng, a professor at Southern University of Science and Technology, Xiao Wenjing, the dean of the School of Chemistry at Central China Normal University, Tang Wenjun, a researcher at the Institute of Organic Chemistry, Chinese Academy of Sciences, as well as the chairmen of several biopharmaceutical enterprises and members of industry associations attended this conference.
This conference was presided over by Dr. Li Shuo, the vice president of Pingshan Biomedical Research Institute of Southern University of Science and Technology, and Dr. Ye Weiping, the chairman of Shenzhen Huaxian Pharmaceutical Technology Co., LTD.
Liu Weidong said in his speech that Pingshan District, as a key layout area for the biomedicine industry in Shenzhen's "20+8" industrial clusters, has concentrated on the layout of biomedicine, high-end medical devices, big health, and future industries such as cells and genes. It has the first batch of national bioindustry bases in China and the only one in Shenzhen, with a total planned area of 3.29 square kilometers. After years of development, An advanced manufacturing cluster of the biomedicine industry has been formed. By the end of July 2024, Pingshan had gathered 1,235 biopharmaceutical enterprises, among which 128 were biopharmaceutical enterprises, covering the complete chain of drug research and development, production and industrialization. In recent years, the research and development technology in the pharmaceutical field has developed rapidly, and international competition has intensified increasingly. Green synthesis and small molecule drug research and development, as important areas of modern drug research, have broad application prospects and huge development potential. At the same time, they also face multiple challenges such as technology, market, regulations and competition, which requires the joint efforts of all entrepreneur and scientist friends. To enhance the ability of drug research and development and innovation.

Zhang Xumu pointed out that this conference is an annual grand event. Leaders from relevant government departments, renowned experts and academicians, industry scholars, and business leaders have gathered in Pingshan. It will attract enterprises from the upstream, midstream and downstream of the green catalytic asymmetric synthesis industry of chiral drugs and the small molecule innovative drug industry, focus on the industrial ecosystem in this field, analyze industrial policies, and discuss hot topics. Build a bridge for the integration of government, industry, research, academia and capital, enhance the overall competitiveness of Shenzhen's green drug synthesis industry and small molecule new drug industry both at home and abroad, and promote the green and high-quality development of the new drug industry.

At the annual meeting, many guests engaged in in-depth exchanges on cutting-edge medical technologies. He Zhendan shared "Research on Traditional Chinese Medicine and New Drugs for Immune and Antiviral Infections". Li Wenbao expounded on "The Research and Development Progress of Small Molecule Innovative Drugs with Marine Characteristics". Wang Peng presented "Innovations of Synthetic Biology in the Research and Development of Nucleic Acid Drugs". Xiao Wenjing focuses on "Organic Photochemical Synthesis". Tang Wenjun introduced "High-Efficiency Catalysis Promotes Disruptive Synthesis Processes".
In addition, Dr. Zhang Jiancun, the chairman of Guangzhou Hengnuokang Pharmaceutical Technology Co., LTD., Dr. Xi Ning, the CEO of Zhongshan Yino Weishen New Drug Research and Development Co., LTD., Dr. Zhou Zhangtao, the CTO of Shenzhen Huaxian Pharmaceutical Technology Co., LTD., Dr. He Wei, the senior director of Hangzhou Anuo Biomedical Technology Co., LTD., and many other business representatives delivered wonderful keynote speeches respectively. Together, they presented a feast of ideas in the field of medical technology to the participants.
At the roundtable forum on "Innovative Development Trends in the Biomedical Industry" hosted by Secretary-General Zhang Zhuangli, guests such as Wang Peng, Xiao Wenjing, Tang Wenjun, Li Shuo, and Liu Xiaoyu engaged in a heated discussion. After the roundtable forum, the guests also visited Guangdong Raffles Pharmaceutical Technology Co., LTD., bringing the meeting to a climax.

During the meeting, Zhu Shaoxuan, the executive president of the Guangdong Biomedical Innovation Technology Association, presented certificates to the expanded members of the Raw Materials Professional Committee of the Guangdong Biomedical Innovation Technology Association.